

PUBLIC HEALTH NEWS

A monthly newsletter brought to you by San Joaquin County Public Health Services

VOL. 1, ISSUE 1

MAY 2022

Topic of the Month: COVID-19 Therapeutics

[Available Outpatient Therapeutic Options for COVID-19](#) | [Test-to-Treat Site Locator](#) | [COVID-19 Therapeutic Distribution Locator](#)

Welcome!



In our launch of a public health newsletter for San Joaquin County, our first topic of the month will be COVID-19 Therapeutics for non-hospitalized patients.

Available Outpatient Therapeutic Options for COVID-19

There are multiple COVID-19 treatments available for people at risk of disease progression. Speak with a healthcare provider when seeking the best treatment option for you. All treatments are available regardless of vaccination status. Please see the chart below for currently authorized COVID-19 therapeutics available. These treatments work best when given as soon as possible after testing positive (1).

SARS-CoV-2 Negative (-)		SARS-CoV-2 Positive (+)
Not Exposed Pre-Exposure Prophylaxis (PrEP)	Exposed Post-Exposure Prophylaxis (PEP)	Mild to Moderate Illness Treatment
Long-Acting Monoclonal Antibody • Tixagevimab/ cilgavimab (Evusheld)	Currently no authorized treatments in this category	Monoclonal Antibodies • Bebtelovimab
		Antivirals • Nirmatrelvir/ritonavir (Paxlovid) • Remdesivir (Veklury) • Molnupiravir (Lagevrio)

Antivirals vs. Monoclonal Antibodies

Antivirals interfere with the way the COVID-19 virus replicated and reproduces, while monoclonal antibodies will temporarily supply your body with the COVID-19 antibodies required to fight illness.

Treatments for people who test positive for COVID-19

There are multiple treatment options available for non-hospitalized people who test positive for COVID-19 and exhibit symptoms. Treatments are listed as stated by the NIH, based on the level of activity against currently circulating virus variants (2).

Preferred Therapies - Listed in order of preference.



- 1. Paxlovid (Nirmatrelvir/ritonavir)**
 - a. Therapy Type:** Antiviral pills
 - b. Available for:** Patients with mild to-moderate COVID-19 who are at risk for disease progression, within 5 days of symptom onset
 - c. Dosage:** Two pills daily, for 5 days
 - d. Age groups authorized for treatment:** 12 years and older and weighing at least 40 kg (about 88 pounds)
 - e. Special Notes:** Consult with your kidney/liver specialist before use. Soon to be available at OptumServe test sites.
- 2. Remdesivir (Veklury)**
 - a. Therapy Type:** Antiviral IV
 - b. Available for:** Patients with mild to-moderate COVID-19 who are at risk for disease progression, within 7 days of symptom onset
 - c. Dosage:** 3 consecutive days of IV infusion
 - d. Age groups authorized for treatment:** FDA approved in 28 days of age and older and weighing at least 3 kg (about 7 pounds).
 - e. Special Notes:** Due to the requirement of 3 days of infusion, it may be difficult to find an administering facility for this treatment.

Treatments for people who test positive for COVID-19 (Cont.)

Alternative Therapies - Listed in alphabetical order. For use **ONLY** when neither of the preferred therapies are available or clinically appropriate

- **Bebtelovimab**

- a. **Therapy Type:** Monoclonal Antibody IV
- b. **Available for:** Patients with mild to-moderate COVID-19 who are at risk for disease progression, within 7 days of symptom onset
- c. **Dosage:** Single one-time IV injection
- d. **Age groups authorized for treatment:** 12 years and older and weighing at least 40 kg (about 88 pounds)
- e. **Special Notes:** Currently the only monoclonal antibody treatment available for use. The following facilities are administering Bebtelovimab:
 - Adventist Health Lodi Memorial
 - Kaiser Hospital Manteca
 - Kaiser Stockton Clinic
 - St. Joseph's Medical Center
 - Sutter Tracy Community Hospital
 - San Joaquin General Hospital
 - San Joaquin County Clinics (Call 209-468-6820)

- **Molnupiravir (Lagevrio)**

- a. **Therapy Type:** Antiviral pills
- b. **Available for:** Patients with mild to-moderate COVID-19 who are at risk for disease progression, within 5 days of symptom onset
- c. **Dosage:** Two pills daily, for 5 days
- d. **Age groups authorized for treatment:** 18 years and older
- e. **Special Notes:** Consult with your primary care physician regarding its decreased effectiveness compared to other treatment options

Preventative treatments for vulnerable populations

For individuals who are **immunocompromised**, there is one pre-exposure prophylaxis available for use with a prescription from a physician.

- **Evusheld (Tixagevimab/cilgavimab)**


- a. **Therapy Type:** Long Acting Monoclonal Antibody intramuscular injections
- b. **Available for:** Patients who have moderate to severe immune compromise due to a medical condition, who have not been exposed and are not experiencing symptoms
- c. **Dosage:** Two separate consecutive injections given on the same day
- d. **Age groups authorized for treatment:** 12 years and older and weighing at least 40 kg (about 88 pounds)
- e. **Special Notes:** The following facilities are administering Evusheld:
 - San Joaquin County Clinics
 - San Joaquin General Hospital
 - Kaiser Hospital Manteca
 - Kaiser Stockton Clinics.

You may also try other locations outside of the county.



Test-to-Treat Site Locator

The federal government has launched multiple Test-to-Treat locations where a person can get tested, receive a prescription for an oral antiviral, and have their prescription filled all at one location. These “One Stop Test-to-Treat” sites are available at select locations.



To find a Test-to-Treat location near you, please visit:

<https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/>

Please note: Locations offering Test-to-Treat services are indicated with a **BLUE** dot.

COVID-19 Therapeutic Distribution Locator

The map linked below indicates which locations have received distributions of the following therapies: Paxlovid, Bebtelovimab, Evusheld, and Molnupiravir. This map may provide general knowledge about therapeutics in your area. Patients should not contact locations directly unless instructed to do so by their healthcare provider.



To find the availability of COVID therapeutics near you, please visit:

<https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>

Newsletter Key Term Definitions

ASPR: Office of the Assistant Secretary for Preparedness & Response

EUA: Emergency Use Authorization

FDA: Food and Drug Administration

IV: Intravenous

NIH: National Institutes of Health

Sources

- (1) [CDPH Get the Facts on Treatments](#)
- (2) [NIH COVID-19 Treatment Guidelines](#)

San Joaquin County Public Health Services
1601 E. Hazelton Ave, Stockton, CA, 95205

Visit us at: www.sjcphs.org | [Facebook](#) | [Twitter](#) | [Instagram](#)

